HC Wainwright & Co. Initiates Coverage On Dianthus Therapeutics with Buy Rating, Announces Price Target of $40
Portfolio Pulse from Benzinga Newsdesk
HC Wainwright & Co. has initiated coverage on Dianthus Therapeutics (NASDAQ:DNTH) with a Buy rating and a price target of $40.
May 16, 2024 | 10:25 am
News sentiment analysis
Sort by:
Descending
POSITIVE IMPACT
HC Wainwright & Co. has initiated coverage on Dianthus Therapeutics with a Buy rating and a price target of $40.
The initiation of coverage with a Buy rating and a price target of $40 by a reputable analyst firm like HC Wainwright & Co. is likely to positively impact the stock price of Dianthus Therapeutics in the short term.
CONFIDENCE 90
IMPORTANCE 80
RELEVANCE 100